American Journal of Cardiology
Volume 97, Issue 8, Supplement 1 , Pages S77-S81 , 17 April 2006

An Assessment of Statin Safety by Hepatologists

  • David E. Cohen, MD, PhD

      Affiliations

    • Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School and Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston, Massachusetts, USA
    • Corresponding Author InformationAddress for reprints: David E. Cohen, MD, PhD, Division of Gastroenterology, Brigham and Women’s Hospital, Thorn 1405, 75 Francis Street, Boston, Massachusetts 02115.
    • ,
  • Frank A. Anania, MD

      Affiliations

    • Emory University School of Medicine, Atlanta, Georgia, USA
    • ,
  • Naga Chalasani, MD

      Affiliations

    • Indiana University School of Medicine, Indianapolis, Indiana, USA.

References 

  1. Chalasani N . Statins and hepatotoxicity (focus on patients with fatty liver) . Hepatology . 2005;41:690–695
  2. Lipitor (atorvastatin) [package insert] . New York, NY: Pfizer Inc; 2004;
  3. Vytorin (ezetimibe-simvastatin) [package insert] . North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2005;
  4. Zetia (ezetimibe) [package insert] . North Wales, PA: Merck/Schering-Plough Pharmaceuticals; 2005;
  5. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values . Hepatology . 2003;37:1286–1292
  6. Sniderman AD . Is there value in liver function test and creatine phosphokinase monitoring for statin use? . Am J Cardiol . 2004;94(suppl):30F–34F
  7. Vuppalanchi R , Teal E , Chalasani N . Patients with elevated baseline liver enzymes do not have higher frequency of hepatoxicity from lovastatin than those with normal baseline liver enzymes . Am J Med Sci . 2005;329:62–65
  8. Chalasani N , Aljadhey H , Kesterson J , Murray MD , Hall SD . Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity . Gastroenterology . 2004;126:1287–1292
  9. Mevacor (lovastatin) [package insert] . Whitehouse Station, NJ: Merck & Co. Inc; 2005;
  10. Zocor (simvastatin) [package insert] . Whitehouse Station, NJ: Merck & Co. Inc; 2004;
  11. Lescol (fluvastatin) [package insert] . East Hanover, NJ: Novartis; 2003;
  12. Pravachol (pravastatin) [package insert] . Princeton, NJ: Bristol-Myers Squibb; 2004;
  13. Crestor (rosuvastatin) [package insert] . Wilmington, DE: AstraZeneca; 2005;
  14. de Denus S , Spinler SA , Miller K , Peterson AM . Statins and liver toxicity (a meta analysis) . Pharmacotherapy . 2004;24:584–591
  15. Russo MW , Galanko JA , Shrestha R , Fried MW , Watkins P . Liver transplantation for acute liver failure from drug induced liver injury in the United States . Liver Transpl . 2004;10:1018–1023
  16. Gotto AM . Safety and statin therapy. Reconsidering the risks and benefits . Arch Intern Med . 2003;163:657–659
  17. Law MR , Rudnicka AR . Statin safety (evidence from the published literature) . Am J Cardiol . 2006;97(suppl 8A):52C–60C
  18. Pelli N , Setti M , Ceppa P , Toncini C , Indiveri F . Autoimmune hepatitis revealed by atorvastatin . Eur J Gastroenterol Hepatol . 2003;15:921–924
  19. Siddiqui J, Raina D, Abraham A, Alla V, Chaslasani N, Wu GY, et al. Autoimmune hepatitis induced by statins . [abstract] Gastroenterology . 2005;128:A171
  20. Tolman KG . The liver and lovastatin . Am J Cardiol . 2002;89:1374–1380
  21. Smith CC , Bernstein LI , Davis RB , Rind DM , Shmerling RH . Screening for statin-related toxicity (The yield of transaminase and creatine kinase measurements in a primary care setting) . Arch Intern Med . 2003;163:688–692
  22. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States . Gastroenterology . 2002;122:1500–1511
  23. Neuschwanter-Tetri BA , Caldwell SH . Nonalcoholic steatohepatitis (summary of an AASLD single topic conference) . Hepatology . 2003;37:1202–1219
  24. Rallidis LS , Drakoulis CK , Parasi AS . Pravastatin in patients with nonalcoholic steatohepatitis (results of a pilot study) . Atherosclerosis . 2004;174:193–196
  25. Horlander JC , Kwo PY , Cummings OW , Koukoulis G . Atorvastatin for the treatment of NASH [abstract] . Gastroenterology . 2001;120:A544
  26. Kiyici M , Gulten M , Gurel S , et al.   Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis . Can J Gastroenterol . 2003;17:713–718
  27. Zimmerman HJ . Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver . New York: Appleton-Century-Crofts; 1978; 181–185, 363–364
  28. Bjornsson E , Olsson R . Outcome and prognostic markers in severe drug-induced liver disease . Hepatology . 2005;42:481–489
  29. Senior JR . Regulatory perspective . In:  Kaplowitz N ,  DeLeve LD editor. Drug Induced Liver Disease . New York: Marcel Dekker, Inc; 2003;p. 739–754

PII: S0002-9149(05)02147-8

doi: 10.1016/j.amjcard.2005.12.014

American Journal of Cardiology
Volume 97, Issue 8, Supplement 1 , Pages S77-S81 , 17 April 2006

Article Tools